Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Esser

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2024
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infectionChristine Tkaczyk, Michael Newton, Mun Mun Patnaik, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Infectious Diseases and Therapy|September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized TrialF D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Plos One|April 13, 2016
Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial VirusSarah V Maifeld, Bodrey Ro, Hoyin Mok, et al.
Science Translational Medicine|July 20, 2022
A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaquesJoseph P Nkolola, Jingyou Yu, Huahua Wan, et al.
Clinical and Vaccine Immunology : CVI|April 13, 2007
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccinesSuzanne M Garland, Marc Steben, Mauricio Hernandez-Avila, et al.
Nature Communications|October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.
Journal of Clinical Microbiology|November 14, 2014
Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremiaBatu K Sharma-Kuinkel, Yuling Wu, David E Tabor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2022
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCharu Aggarwal, Nabil F Saba, Alain Algazi, et al.
Plos One|January 10, 2013
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assaysShih-Wen Lin, Arpita Ghosh, Carolina Porras, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2024
In vivo mRNA expression of a multi-mechanistic mAb combination protects against Staphylococcus aureus infectionChristine Tkaczyk, Michael Newton, Mun Mun Patnaik, et al.
Lancet (London, England)|June 5, 2009
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trialNubia Muñoz, Ricardo Manalastas, Punee Pitisuttithum, et al.
Infectious Diseases and Therapy|September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized TrialF D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Plos One|April 13, 2016
Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial VirusSarah V Maifeld, Bodrey Ro, Hoyin Mok, et al.
Science Translational Medicine|July 20, 2022
A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaquesJoseph P Nkolola, Jingyou Yu, Huahua Wan, et al.
Clinical and Vaccine Immunology : CVI|April 13, 2007
Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccinesSuzanne M Garland, Marc Steben, Mauricio Hernandez-Avila, et al.
Nature Communications|October 14, 2025
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19Rhiannon Edge, Sam Matthews, Bahar Ahani, et al.
Journal of Clinical Microbiology|November 14, 2014
Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremiaBatu K Sharma-Kuinkel, Yuling Wu, David E Tabor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2022
Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCharu Aggarwal, Nabil F Saba, Alain Algazi, et al.
Plos One|January 10, 2013
HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assaysShih-Wen Lin, Arpita Ghosh, Carolina Porras, et al.
Pageof 10